Matches in Wikidata for { <http://www.wikidata.org/entity/Q65381447> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q65381447 description "clinical trial" @default.
- Q65381447 description "ensayu clínicu" @default.
- Q65381447 description "klinisch onderzoek" @default.
- Q65381447 description "клінічне випробування" @default.
- Q65381447 name "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease" @default.
- Q65381447 name "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease" @default.
- Q65381447 type Item @default.
- Q65381447 label "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease" @default.
- Q65381447 label "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease" @default.
- Q65381447 prefLabel "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease" @default.
- Q65381447 prefLabel "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease" @default.
- Q65381447 P1132 Q65381447-32B16DBA-9B3D-4F60-9E01-F0198DDF5D28 @default.
- Q65381447 P1476 Q65381447-618EF388-3180-4082-8395-FFA0707C1A73 @default.
- Q65381447 P17 Q65381447-2B1BBA29-879B-4DD6-B705-96242B32165D @default.
- Q65381447 P17 Q65381447-4A521E78-BEEA-44B6-91E6-15CAC20280EF @default.
- Q65381447 P17 Q65381447-62AE2958-BE55-4B75-BE4A-E73B06016796 @default.
- Q65381447 P17 Q65381447-86C9EB05-3D23-40FD-9915-690094F7D7EB @default.
- Q65381447 P17 Q65381447-8BF0279B-8E11-4A58-8F5F-F18B90A634E2 @default.
- Q65381447 P17 Q65381447-B37A1856-BB91-4E78-8FBC-1A5723B61A72 @default.
- Q65381447 P2899 Q65381447-96A719F7-C2C5-45BC-AEEA-9E4D2FD69441 @default.
- Q65381447 P3098 Q65381447-3267D951-2208-4F32-BE17-1865326BA538 @default.
- Q65381447 P31 Q65381447-1E37969F-6B17-4D26-8B4B-27EAF5508197 @default.
- Q65381447 P4135 Q65381447-84D7A231-3308-4DDB-BB14-FF4402BC4C76 @default.
- Q65381447 P4844 Q65381447-637A41EA-1925-49A3-9614-664CB824821C @default.
- Q65381447 P580 Q65381447-C70CC9C5-CD1E-4105-AC90-34EDAE15A40F @default.
- Q65381447 P582 Q65381447-FE352423-0185-413D-8711-81FEEE85B78E @default.
- Q65381447 P6099 Q65381447-2F32C6E8-1346-445B-B325-CE5611CBD302 @default.
- Q65381447 P6153 Q65381447-132FB876-7C29-4A7E-A2A1-AB4480E2D5CD @default.
- Q65381447 P6153 Q65381447-17B10314-A7C5-4283-BFAF-D6E0F4B5CBFB @default.
- Q65381447 P6153 Q65381447-4DAD52CB-2EAC-43DF-B83C-BE743771AA08 @default.
- Q65381447 P6153 Q65381447-6844EBF0-B197-4C6E-93D6-3C0E721EA895 @default.
- Q65381447 P6153 Q65381447-9B8CA47E-C6DC-4CDF-8AE0-4605DD43C47E @default.
- Q65381447 P6153 Q65381447-AB9B2709-BDF1-44A2-85BD-F070E1D29B4C @default.
- Q65381447 P6153 Q65381447-FDBC9553-5B64-432D-B267-6E6434B330FC @default.
- Q65381447 P8363 Q65381447-31770B14-AE7C-4C9F-8056-FB64BC553F46 @default.
- Q65381447 P1132 "+410" @default.
- Q65381447 P1476 "A Phase II, Multicentre, Double-blind, Randomised, Dose Range Finding Placebo Controlled Study of Rifaximin-EIR Tablet: Clinical Effectiveness and Tolerability in the Treatment of Moderate, Active Crohn's Disease" @default.
- Q65381447 P17 Q142 @default.
- Q65381447 P17 Q183 @default.
- Q65381447 P17 Q28 @default.
- Q65381447 P17 Q36 @default.
- Q65381447 P17 Q38 @default.
- Q65381447 P17 Q801 @default.
- Q65381447 P2899 "+18" @default.
- Q65381447 P3098 "NCT00528073" @default.
- Q65381447 P31 Q30612 @default.
- Q65381447 P4135 "+75" @default.
- Q65381447 P4844 Q416073 @default.
- Q65381447 P580 "2007-09-01T00:00:00Z" @default.
- Q65381447 P582 "2009-03-01T00:00:00Z" @default.
- Q65381447 P6099 Q42824440 @default.
- Q65381447 P6153 Q2071553 @default.
- Q65381447 P6153 Q2890053 @default.
- Q65381447 P6153 Q2902227 @default.
- Q65381447 P6153 Q30253940 @default.
- Q65381447 P6153 Q319239 @default.
- Q65381447 P6153 Q3803602 @default.
- Q65381447 P6153 Q911561 @default.
- Q65381447 P8363 Q78089383 @default.